Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Research Reports

Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Research Reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Streetwise Reports (11/23/2022)

Pharma Co. Gains Approval for SARS-CoV-2 Drug

Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection.

Tags: Biotechnology / Pharmaceuticals

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Streetwise Reports (11/22/2022)

Global Drug Co. Offers US$1.35B To Boost Hematology Assets

Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share.

Tags: Biotechnology / Pharmaceuticals

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

Research Report

Dr. Yale Jen (11/22/2022)

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock

The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.

Tags: Biotechnology / Pharmaceuticals

Life Sciences Co. Exceeds Expectations in Q3/22

Research Report

Dr. Andre Uddin (11/22/2022)

Life Sciences Co. Exceeds Expectations in Q3/22

During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

FDA Awards Breakthrough Therapy Status for AMD Drug

Streetwise Reports (11/21/2022)

FDA Awards Breakthrough Therapy Status for AMD Drug

Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Won't See Bump in Sales From New COVID Drug

Research Report

Dr. Andre Uddin (11/18/2022)

Pharma Co. Won't See Bump in Sales From New COVID Drug

The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Hopes To Turn US$30M Into US$2B

Streetwise Reports (11/17/2022)

Biopharma Co. Hopes To Turn US$30M Into US$2B

CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

Streetwise Reports (11/16/2022)

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data

4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.

Tags: Biotechnology / Pharmaceuticals

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

Streetwise Reports (11/14/2022)

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment

This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

UK Co. Buys NARCAN® Nasal Spray Maker

Streetwise Reports (11/14/2022)

UK Co. Buys NARCAN® Nasal Spray Maker

Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.

Tags: Biotechnology / Pharmaceuticals

Biologics Co. Doubles Revenue in Q3/22

Streetwise Reports (11/11/2022)

Biologics Co. Doubles Revenue in Q3/22

ADMA Biologics Inc. shares traded 27.5% higher after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.

Tags: Biotechnology / Pharmaceuticals

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

Streetwise Reports (11/11/2022)

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Trades 200% Higher

Streetwise Reports (11/10/2022)

Pharma Co. Trades 200% Higher

Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.

Tags: Biotechnology / Pharmaceuticals

Nine Stocks Expert Says Should Pique Your Interest

Contributed Opinion

Clive Maund (11/09/2022)

Nine Stocks Expert Says Should Pique Your Interest

Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.

Tags: GoldBiotechnology / PharmaceuticalsCritical MetalsTechnologyBase MetalsSilver

Clean Nuclear Med Tech With Quantum Blue Sky

Contributed Opinion

Penny Queen (11/09/2022)

Clean Nuclear Med Tech With Quantum Blue Sky

With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.

Tags: Biotechnology / Pharmaceuticals

Healthcare Firm Offers US$295M for Ophthalmology Co.

Streetwise Reports (11/08/2022)

Healthcare Firm Offers US$295M for Ophthalmology Co.

Shares of Oyster Point Pharma Inc. traded 38.5% higher after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Signs Global License Deal for Eye Drops

Streetwise Reports (11/08/2022)

Pharma Co. Signs Global License Deal for Eye Drops

Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances.

Tags: Biotechnology / Pharmaceuticals

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines

Streetwise Reports (11/03/2022)

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines

Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Earns Big Rewards from Global License Deal

Streetwise Reports (11/02/2022)

Pharma Co. Earns Big Rewards from Global License Deal

Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Trades 39% Higher

Streetwise Reports (11/01/2022)

Biopharma Co. Trades 39% Higher

Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant.

Tags: Biotechnology / Pharmaceuticals

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current

Research Report

(10/31/2022)

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current

This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial

Streetwise Reports (10/28/2022)

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial

Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer.

Tags: Biotechnology / Pharmaceuticals

Potential ROI With German Biopharma Co. Notable

Research Report

Dr. Elemer Piros (10/27/2022)

Potential ROI With German Biopharma Co. Notable

This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results

Streetwise Reports (10/25/2022)

Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results

Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age.

Tags: Biotechnology / Pharmaceuticals

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'

Contributed Opinion

Clive Maund (10/25/2022)

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'

Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy it.

Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 147 Next

More Experts